Picture of Dignitana AB logo

DIGN Dignitana AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-10.88%
3m-26.13%
6m-39.95%
1yr-64.23%
Volume Change (%)
10d/3m+108.6%
Price vs... (%)
52w High-67%
50d MA-12.61%
200d MA-35.21%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value16.01
Price to Tang. Book24.85
Price to Free Cashflown/a
Price to Sales1.35
EV to EBITDA1,504.18

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-109.28%
Return on Equity-110.19%
Operating Margin-17.46%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Dignitana AB EPS forecast chart

Profile Summary

Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 24th, 2007
Public Since
June 18th, 2009
No. of Employees
27
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
70,474,155
Blurred out image of a map
Address
Traktorgranden 3, LUND, 226 60
Web
https://dignitana.com/
Phone
+46 46163090
Contact
Mikael Wahlgren
Auditors
Ohrlings PricewaterhouseCoopers AB

DIGN Share Price Performance

Upcoming Events for DIGN

Dignitana AB Annual Shareholders Meeting

Q1 2024 Dignitana AB Earnings Release

Dignitana AB Annual Shareholders Meeting

Q2 2024 Dignitana AB Earnings Release

Similar to DIGN

Picture of Acarix AB logo

Acarix AB

se flag iconOMX Nordic Exchange Stockholm

Picture of ADDvise AB (publ) logo

ADDvise AB (publ)

se flag iconOMX Nordic Exchange Stockholm

Picture of ADDvise AB (publ) logo

ADDvise AB (publ)

se flag iconOMX Nordic Exchange Stockholm

Picture of Aegirbio AB logo

Aegirbio AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Arcoma AB logo

Arcoma AB

se flag iconOMX Nordic Exchange Stockholm

FAQ